News
  Date Title View
Oct 30, 2017
BURLINGTON, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its third-quarter 2017 financial results on Monday, November 6, 2017, at 4:30 p.m. ET. The dial-in numb...
Oct 11, 2017
BURLINGTON, Mass., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $25.50 per share.  The gross proceeds from this offering are expected to be approximately $122.4 milli...
Oct 10, 2017
BURLINGTON, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell 4,000,000 shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to pur...
Oct 9, 2017
Oct 6, 2017
Innovative, non-opioid, intra-articular therapy, proven to deliver meaningful analgesia over 12 weeks in patients with moderate to severe OA knee painProduct label also includes positive data from type 2 diabetes study Commercial supply expected to be available by late Octobe...
Sep 7, 2017
BURLINGTON, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today will present results from an analysis that found patients treated in clinical trials of Zilretta™ (FX006), its lead candidate for the treatment of osteoarthritis (OA) knee pain, had a statistically significantly lower use o...
Aug 30, 2017
BURLINGTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2017 Wells Fargo Healthcare Conference on Wednesday, September 6, 2017 at 9:40am ET at the Westin...
Aug 8, 2017
Commercial preparations for the potential launch of ZilrettaTM (FX006) advancing rapidlyStudy evaluating the safety of repeat administration of Zilretta has been fully enrolledManagement strengthened with recent appointments of Mark Levine, General Counsel and Corporate Secretary an...
Aug 1, 2017
BURLINGTON, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its second-quarter 2017 financial results on Tuesday, August 8, 2017, at 4:30 p.m. ET. The dial-in numb...
Jul 10, 2017
Management to discuss the latest plans for the potential launch of ZilrettaTMClinical experts to share perspectives on ZilrettaCompany to introduce new pipeline candidate (FX101) BURLINGTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Flexio...
FirstPrevious
2
... NextLast
= add release to Briefcase